These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2407775)

  • 1. Now and future influenza vaccines.
    Ruben FL
    Infect Dis Clin North Am; 1990 Mar; 4(1):1-10. PubMed ID: 2407775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated influenza virus vaccines in children.
    Ruben FL
    Clin Infect Dis; 2004 Mar; 38(5):678-88. PubMed ID: 14986252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Aug; 7(6):713-9. PubMed ID: 18665769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.
    Li S; Perdue ML; Patzer E
    Dev Biol (Basel); 2002; 110():135-41. PubMed ID: 12477316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-influenza vaccination in children].
    Battistini A; Ollari R; Dodi L
    Pediatr Med Chir; 1985; 7(3):369-74. PubMed ID: 3915545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory and clinical evaluation of new live influenza virus vaccines. Need for minimum requirements.
    Huygelen C
    Dev Biol Stand; 1977 Jun 1-3; 39():155-60. PubMed ID: 342307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines to protect humans from pandemic avian influenza strains.
    Campbell JD
    Md Med; 2006; 7(1):15-8. PubMed ID: 16613361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of new vaccine technologies for the control of transboundary diseases.
    Swayne DE
    Dev Biol (Basel); 2004; 119():219-28. PubMed ID: 15742632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.